Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back In The Saddle: Texas Biotech Opexa Re-Enters The Clinic With MS Immunotherapy

This article was originally published in The Pink Sheet Daily

Executive Summary

After a series of restructurings, a manufacturing upgrade, multiple meetings with FDA and a modest fundraising, Opexa is initiating a Phase IIb trial of its renamed T-cell immune therapy Tcelna, this time in secondary progressive MS.

You may also be interested in...



Opexa Goes Into Hold Mode, Awaiting Secondary Progressive MS Data

Biotech cuts staff by 30%, hoping for good news from Phase IIb trial due in the fourth quarter. Status of second candidate nearing the clinic is uncertain.

Opexa Pins Hope On Failed MS Vaccine’s Relapse Rate

More baseline lesions for personalized drug group cited in Phase IIb blowup

Opexa Pharmaceuticals Inc.

Opexa Pharmaceuticals was founded in February 2001 to develop therapeutic vaccines for autoimmune diseases. Based on techniques designed by co-founder Jingwu Zhang of Baylor College of Medicine, its first product is a vaccine comprised of autologous myelin-reactive T-cells that stimulate the immune response of patients with multiple sclerosis. The selectivity of the process enables greater efficacy with fewer side effects than existing therapies for MS.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel